Cytogenetics and survival of multiple myeloma: isolated and combined effects
In conclusion, del(13q), t(4;14) and del(17p) seem to represent independent poor prognostic factors for patients with MM. Teaser In a large cohort of unselected MM patients (n=432), the presence of del(13q), t(4;14) and del(17p) was independently associated with poorer overall survival, after adjustment for a variety of clinical and laboratory parameters. The poor prognosis seemed more pronounced among patients with combinations of two adverse cytogenetic abnormalities. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - March 29, 2016 Category: Cancer & Oncology Source Type: research

Comparative Effectiveness of Newer Tyrosine Kinase Inhibitors versus Imatinib in the First-Line Treatment of Chronic Phase Chronic Myeloid Leukemia across Risk Groups: a Systematic Review and Meta-analysis of Eight Randomized Trials
Conclusions In first-line treatment, the NG-TKIs as a category showed greater effectiveness in MMR and prevention of AP/BC progression. Risk stratification was not found to impact on the RR of CCyR and MMR. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - March 29, 2016 Category: Cancer & Oncology Source Type: research

Molecular Cytogenetic Analysis of Chromosome 8 Aberrations in Patients With Multiple Myeloma Examined in 2 Different Stages, at Diagnosis and at Progression/Relapse
Conclusion In the current study, chromosome 8 aberrations were highly heterogeneous, were presented at diagnosis in patients with advanced clinical stage, and were associated with worse overall survival. We have not confirmed the increase of frequency aberration of chromosome 8 in disease progression. The findings demonstrate the importance of fluorescence in situ hybridization examination of chromosome 8 in newly diagnosed patients with MM. Micro-Abstract This retrospective study of 62 patients with multiple myeloma examined at 2 different phases (diagnosis and progression/relapse), revealed chromosome 8 aberrations in 2...
Source: Clinical Lymphoma Myeloma and Leukemia - March 24, 2016 Category: Cancer & Oncology Source Type: research

Mortality and Vascular Events Among Elderly Patients With Chronic Myeloid Leukemia: A Retrospective Analysis of Linked SEER-Medicare Data
Conclusion Elderly patients with CML had greater mortality and greater rates of MI, stroke, PE, and PAD than did noncancer patients. The event rates were not elevated among the TKI-treated (primary imatinib) patients, suggesting that the VE risk in these patients with CML was driven primarily by the underlying factors associated with CML. Micro-Abstract Tyrosine-kinase inhibitor (TKI) treatment of chronic myeloid leukemia (CML) can be associated with vascular events (VEs). We examined the event rates and mortality among elderly patients with and without CML using linked cancer registry and Medicare claims data from 2003 t...
Source: Clinical Lymphoma Myeloma and Leukemia - March 21, 2016 Category: Cancer & Oncology Source Type: research

Extramedullary Cardiac Multiple Myeloma—A Case Report and Contemporary Review of the Literature
We present the case of a 61-year-old female patient 47 days after autologous stem cell transplant for MM who developed cardiac tamponade owing to extramedullary recurrence of myeloma, pulmonary embolism, and takotsubo cardiomyopathy. We performed a review of the published studies of all cases of MM presenting at diagnosis or relapse with cardiac or pericardial involvement in the past 25 years. Including our patient, 34 patients with plasmacytoma involving cardiac or pericardial structures were identified from the literature search. Approximately equal numbers of patients were male and female (42% and 57%, respectively). Th...
Source: Clinical Lymphoma Myeloma and Leukemia - March 19, 2016 Category: Cancer & Oncology Source Type: research

Outcome Disparities in Caucasian and non-Caucasian Patients with Myeloproliferative Neoplasms
Conclusion This study shows for the first time that race can influence clinical outcomes in myeloproliferative neoplasms. This study highlights the need for greater representation of non-Caucasian patients in studies investigating vascular risk factors in MPNs. Teaser This is a single institution retrospective experience examining the effect of race and ethnicity on disease phenotype in myeloproliferative neoplasms. We demonstrate racial disparities in the outcomes of myeloproliferative neoplasm with Caucasian ethnicities being relatively protected against cardiovascular thrombosisis and hemorrhagic complications. African ...
Source: Clinical Lymphoma Myeloma and Leukemia - March 8, 2016 Category: Cancer & Oncology Source Type: research

VANTAGE 095: An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma
Conclusion The combination of vorinostat + bortezomib is active in multiple myeloma patients refractory to novel treatment modalities and offers a new therapeutic option for this difficult-to-treat patient population (clinicaltrials.gov: NCT00773838). Teaser This study was designed to determine efficacy and tolerability of vorinostat in combination with bortezomib in multiple myeloma patients. Patients received 21-day cycles of bortezomib + vorinostat. Objective response rate was 11.3% (95% CI: 6.6%, 17.7%) and median duration of response of 211 days (64-550). Vorinostat + bortezomib is active in multiple myeloma patients ...
Source: Clinical Lymphoma Myeloma and Leukemia - March 5, 2016 Category: Cancer & Oncology Source Type: research

Comprehensive evaluation of adherence to therapy, its associations, and its implications in patients of chronic myeloid leukemia on imatinib
Publication date: Available online 3 March 2016 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Radhika Unnikrishnan, Surendran Veeraiah, Samson Mani, Rejiv Rajendranath, Swaminathan Rajaraman, Grace Sahaya Vidhubala Elangovan, Venkatraman Radhakrishnan, Trivadi S. Ganesan, Tenali G. Sagar, Prasanth Ganesan Adherence to oral therapy over a long-period is important for optimal outcomes in chronic myeloid leukemia (CML). Patients in chronic phase of CML (on imatinib for ≥6 months) were assessed by the Morisky Medication Adherence Scale (MMAS 8) and EORTC Quality of life (QoL) Questionnaire (QLQ C30 an...
Source: Clinical Lymphoma Myeloma and Leukemia - March 4, 2016 Category: Cancer & Oncology Source Type: research

CD10-positive Hairy Cell Leukemia Involving Multiple Deep Lymph Nodes
Publication date: Available online 3 March 2016 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Ling Wang, Anthony S. Tadros, Carl K. Hoh, Huan-You Wang (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - March 4, 2016 Category: Cancer & Oncology Source Type: research

Functional genomic investigation of the molecular biological impact of electron beam radiation in lymphoma cells
Conclusion For the first time, 8 MeV pulse EBR induced genomic changes and their consequence in molecular and biological processes were identified in lymphoma cells. The comprehensive investigation of radiation-mediated responses in cancer cells also revealed the potential therapeutic features of EBR. Teaser Molecular genomic effect of 8 MeV electron beam radiation (EBR) in ascites of Dalton's lymphoma was investigated. Integrative functional genomic analyses identified the radiation responsive genes and corresponding biological responses. The activation of p53, PPAR and SMAD signaling pathways along with G2-M phase arrest...
Source: Clinical Lymphoma Myeloma and Leukemia - March 4, 2016 Category: Cancer & Oncology Source Type: research

Improved Survival of Calreticulin-Mutated Patients Compared With Janus Kinase 2 in Primary Myelofibrosis: A Meta-Analysis
Conclusion The results of the present meta-analysis have confirmed the role of the CALR mutation in the diagnosis of, and as a prognostic tool for, PMF. Our results suggest that patients with the CALR mutation will have better overall survival than patients with the JAK2 mutation in a non-Asian population. Micro-Abstract Calreticulin (CALR) is a recently discovered mutation in patients with primary myelofibrosis (PMF). Six studies (Asian and non-Asian) met the inclusion criteria for the present meta-analysis, which has confirmed the role of the CALR mutation in the diagnosis of, and as a prognostic tool for, PMF. Our resu...
Source: Clinical Lymphoma Myeloma and Leukemia - February 28, 2016 Category: Cancer & Oncology Source Type: research

Prognostic Impact of Serum Heavy/Light Chain Pairs in Patients with Monoclonal Gammopathy of Undetermined Significance and Smoldering Myeloma: Long-Term Results from a Single Institution
Conclusion HLC ratios could be a valuable tool in the risk stratification of patients with SMM and MGUS, speciality in IgG patients. Teaser The aim of the present study is to investigate the prognostic impact of involved and uninvolved HLC pair and HLC ratios on progression in 114 patients diagnosed with SMM and MGUS between 1983 and 2003. Evolving pattern and suppression of any IgM HLC pair were associated with shorter time to progression. Novel HLC assay is a valuable tool in the risk stratification of these patients. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - February 28, 2016 Category: Cancer & Oncology Source Type: research

Loss of CD38 expression in relapsed refractory multiple myeloma
Publication date: Available online 27 February 2016 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Mikiko Ise, Keiko Matsubayashi, Hideki Tsujimura, Kyoya Kumagai (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - February 28, 2016 Category: Cancer & Oncology Source Type: research

Deeper insights into Vanishing Bile Duct Syndrome in lymphoma: A Perplexing Entity
Publication date: Available online 27 February 2016 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Vishwanath Sathyanarayanan, Wai Chin Foo, Michelle Fanale, Jason Robert Westin (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - February 28, 2016 Category: Cancer & Oncology Source Type: research

Essential thrombocythemia associated with germline JAK2 G571S variant and somatic CALR type 1 mutation
Publication date: Available online 27 February 2016 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Irina Panovska-Stavridis, Aleksandar Eftimov, Martin Ivanovski, Aleksandra Pivkova-Veljanovska, Lidija Cevrevska, Sylvie Hermouet, Aleksandar J. Dimovski (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - February 28, 2016 Category: Cancer & Oncology Source Type: research

Molecular cytogenetic analysis of chromosome 8 aberrations in multiple myeloma (MM) patients examined in two different stages, at diagnosis and at progression/relapse
Conclusion In the current study, chromosome 8 aberrations were highly heterogeneous, presented at diagnosis in patients with advanced clinical stage and associated with worse overall survival. We have not confirmed the increase of frequency aberration of chromosome 8 in disease progression. The findings demonstrate the importance of FISH examination of chromosome 8 in newly diagnosed MM patients. Teaser This retrospective study of 62 multiple myeloma patients examined at two different phases, at diagnosis and at progression/relapse, revealed chromosome 8 aberrations in 38.7% patients at diagnosis and at progression/relapse...
Source: Clinical Lymphoma Myeloma and Leukemia - February 28, 2016 Category: Cancer & Oncology Source Type: research

Extramedullary cardiac-multiple myeloma – a case report and a contemporary review of the literature
Conclusion The reporting of all cases to date focused on reporting unusual findings, rather than treatment approaches or new therapeutic strategies which may benefit patients. We suggest a database be formed of all cases of cardiac and pericardial EMPs with a focus on predictive disease variables, standardized staging, outcome and survival to ensure patients are optimally treated in the modern era. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - February 18, 2016 Category: Cancer & Oncology Source Type: research

Allogeneic Transplantation for Patients with Advanced Myelofibrosis: Splenomegaly and High Serum LDH are Adverse Risk Factors for Successful Engraftment
Publication date: Available online 18 February 2016 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Usama Gergis, Emil Kuriakose, Tsiporah Shore, Sebastian Mayer, Tomer Mark, Roger Pearse, Michael Schuster, Eric Feldman, Gail Roboz, Ellen Ritchie, Joseph Scandura, Hanhan Wang, Xi Kathy Zhou, Richard T. Silver, Koen van Besien Thirty consecutive patients underwent hematopoietic stem cell transplantation (HSCT) for myelofibrosis (MF) at our institution. The median age at transplant was 49 years (range, 18-68), 74% of patients had advanced dynamic international prognostic scoring system (DIPPS), and ...
Source: Clinical Lymphoma Myeloma and Leukemia - February 18, 2016 Category: Cancer & Oncology Source Type: research

Evaluating the impact of a switch to nilotinib on imatinib-related chronic low-grade adverse events in patients with CML-CP: the ENRICH study
Conclusions Overall, results from ENRICH demonstrated that switching to nilotinib can mitigate imatinib-related chronic low-grade nonhematologic AEs in patients with CML-CP in conjunction with acceptable safety and achievement of molecular responses. This trial was registered at www.clinicaltrials.gov as NCT00980018. Teaser Chronic treatment-related AEs adversely impact the QOL, treatment adherence, and clinical outcomes of many patients on imatinib. The ENRICH study evaluated the impact of switching 52 such patients to nilotinib. Within 3 months of switching, improvements in imatinib-related AEs and QOL, as well as ongoin...
Source: Clinical Lymphoma Myeloma and Leukemia - February 16, 2016 Category: Cancer & Oncology Source Type: research

Mortality and Vascular Events Among Elderly Patients with Chronic Myeloid Leukemia (CML): A Retrospective Analysis of Linked Seer-Medicare Data
Conclusions Elderly CML patients had higher mortality and higher rates of MI, stroke, PE and PAD than non-cancer patients. Event rates were not elevated among TKI-treated (primary imatinib) patients, suggesting that VE risk in these CML patients was driven primarily by underlying factors associated with CML. Teaser TKI treatment of CML may be associated with vascular events (VE). We examined event rates and mortality among elderly CML and non-cancer patients using linked cancer registry and Medicare claims data, 2003-2010. CML patients had higher mortality and VE rates. Rates were not elevated among TKI (primarily imatinib...
Source: Clinical Lymphoma Myeloma and Leukemia - February 7, 2016 Category: Cancer & Oncology Source Type: research

Improved survival of Calreticuline mutated patients compared to JAK2 in primary myelofibrosis: a meta-analysis
Conclusions This meta-analysis confirms the role of the Calreticulin mutation in the diagnosis and as prognostic tool in PMF patients. Our results suggest that patients with CALR mutation have a better overall survival compared to JAK2 mutated patients in non-Asian population. Teaser Calreticulin (CALR) is a recently discovered in patients with primary myelofibrosis (PMF). Six studies (Asian and non-Asian) met the inclusion criteria of this meta-analysis that confirms the role of the Calreticulin mutation in the diagnosis and as prognostic tool in PMF patients. Our results suggest that patients with CALR mutation have a be...
Source: Clinical Lymphoma Myeloma and Leukemia - February 7, 2016 Category: Cancer & Oncology Source Type: research

Management of Carfilzomib-Associated Cardiac Adverse Events
This article discusses the cardiac-related adverse events that have been reported in clinical studies of carfilzomib and presents a single institution perspective on the prevention and management of cardiac adverse events following treatment with this agent. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - February 4, 2016 Category: Cancer & Oncology Source Type: research

Risk-adapted approach to HLA-matched sibling hematopoietic cell allografting: impact of adjusting conditioning intensity and integrating post-transplant therapeutic interventions
Conclusion This risk-adapted combined approach of selecting conditioning intensity and integrating post-transplant therapies results in lower NRM and encouraging improvement in survival. Our findings warrant confirmation in a large prospective multicenter trial. Teaser Allo-HCT is a curative strategy for various hematologic malignancies. However, success is limited by mortality and relapse. We demonstrate the efficacy of a risk-adapted approach to HLA-matched sibling allo-HCT by adjusting intensity of busulfan according to age, disease risk and existing comorbidities, and by implementing appropriate post-transplant prophyl...
Source: Clinical Lymphoma Myeloma and Leukemia - February 4, 2016 Category: Cancer & Oncology Source Type: research

Adult Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia in Daily Practice: A Multicenter Experience
Conclusions Current state-of-the art management of Ph+ ALL in real-life seems to be incorporation of TKIs to chemotherapy regimens and proceeding to allo-HCT, whenever possible. Teaser In this retrospective, multicenter study, we evaluated the real-life outcomes of adult Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) patients. The best results in terms of survival are achieved in patients, who were treated with tyrosine kinase inhibitors during induction and received allogeneic hematopoietic cell transplantation as part of consolidation. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - February 4, 2016 Category: Cancer & Oncology Source Type: research

Multiple Myeloma in Pregnancy—A Review of the Literature and a Case Series
We report 5 additional cases along with a review of the existing literature. We provide a review of potential treatment regimens and approaches to the management of pregnancy during multiple myeloma. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - February 3, 2016 Category: Cancer & Oncology Source Type: research

Clinical Features and Survival of Patients With Follicular Lymphoma in Korea
Conclusion We could not find definitive differences between our Korean data and the Western data, although we found some trends in the baseline characteristics. Therefore, we hope to develop an understanding of FL and perform more qualitative studies in the future. Micro-Abstract We performed a retrospective analysis of 343 patients diagnosed with follicular lymphoma in Korea who showed some different tendencies compared with patients in Western countries. The grade was high and the stage relatively low. Bcl-2 expression was also low; however, except for these factors, most of the characteristics were similar. (Source: Cl...
Source: Clinical Lymphoma Myeloma and Leukemia - February 3, 2016 Category: Cancer & Oncology Source Type: research

Role of Rituximab and Rituximab Biosimilars in Diffuse Large B-Cell Lymphoma
Publication date: Available online 30 January 2016 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Morton Coleman, Philip E. Lammers, Fabio Ciceri, Ira A. Jacobs Diffuse large B-cell lymphoma (DLBCL), an aggressive non-Hodgkin lymphoma (NHL), is the most-common subtype of NHL. DLBCL can be classified into at least 3 major immunologically distinct types, which contributes to considerable variation in disease prognosis and response to treatment. DLBCL is potentially curable, even when diagnosed at advanced stages. The current standard of care for most patients with untreated or relapsed/refractory DLBCL is che...
Source: Clinical Lymphoma Myeloma and Leukemia - January 30, 2016 Category: Cancer & Oncology Source Type: research

Comorbidities Drive Outcomes for Both Malignancy-Associated and Non–Malignancy-Associated Hemophagocytic Syndrome
Conclusion Malignancy-associated HPS, CCI ≥ 2, age > 50 years, and Medicare patients were associated with a worse in-hospital mortality. In multivariate analysis, greater comorbidity burden appeared to be the single most important predictor of mortality. This suggests that outcomes for adults with HPS are predicated by the extent of organ dysfunction at diagnosis. Micro-Abstract Secondary hemophagocytic syndrome (SHPS) is a rare syndrome that develops in the context of infection, autoimmune disease, or underlying malignancy, resulting in unregulated activation of the immune system. Through a retrospective a...
Source: Clinical Lymphoma Myeloma and Leukemia - January 29, 2016 Category: Cancer & Oncology Source Type: research

Ibrutinib as a Bruton Kinase Inhibitor in the Management of Chronic Lymphocytic Leukemia: A New Agent With Great Promise
Publication date: February 2016 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 16, Issue 2 Author(s): Ogunleye Foluso, Alexander Glick, Michael Stender, Ishmael Jaiyesimi The recent discovery of the role of the B-cell antigen receptor (BCR) signaling pathway in the propagation and maintenance of both normal B-cell function and in B-cell malignancies has highlighted the importance of many protein kinases involved in BCR signal propagation. Considerable research attention has focused on the Bruton tyrosine kinase (BTK) as a potential therapeutic target in B-cell malignancies. Treatment paradigms including ibruti...
Source: Clinical Lymphoma Myeloma and Leukemia - January 23, 2016 Category: Cancer & Oncology Source Type: research

Pharmacokinetics and Safety of Elotuzumab Combined With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma and Various Levels of Renal Impairment: Results of a Phase Ib Study
Conclusion The results of the present study support the use of elotuzumab for the treatment of patients with MM and renal dysfunction without dose adjustment. Micro-Abstract Renal impairment is associated with a poor prognosis in patients with multiple myeloma (MM), and more treatment options are needed. The pharmacokinetics of elotuzumab, a humanized IgG1 monoclonal antibody, combined with lenalidomide and dexamethasone, is not significantly different between patients with MM with and without renal impairment, suggesting that elotuzumab might be administered without dose adjustment for renal function. (Source: Clinical L...
Source: Clinical Lymphoma Myeloma and Leukemia - January 20, 2016 Category: Cancer & Oncology Source Type: research

Successful treatment of hepatitis C infection while receiving concurrent chemotherapy for AL Amyloidosis
Publication date: Available online 18 January 2016 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Eric Chow, Zainab Shahid, Elton Travis Smith, Michal Kamionek, Saad Usmani (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - January 20, 2016 Category: Cancer & Oncology Source Type: research

Differences in Quality of Life Between Bendamustine-Rituximab and R-CHOP/R-CVP in Patients With Previously Untreated Advanced Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma
Conclusion Compared with patients treated with standard therapy, patients treated with BR reported better quality of life in several areas. Teaser Comparative chemotherapy-related quality of life data are lacking. Bendamustine-rituximab (BR) demonstrated noninferiority to R-CHOP (rituximab/cyclosphosphamide/doxorubicin/vincristine/prednisone)/R-CVP (rituximab/cyclophosphamide/vincristine/prednisone) in first-line advanced indolent non-Hodgkin and mantle cell lymphomas. Patients receiving BR reported improvement across many domains, with a few exceptions, of the European Organisation for Research and Treatment of Cancer Qua...
Source: Clinical Lymphoma Myeloma and Leukemia - January 15, 2016 Category: Cancer & Oncology Source Type: research

A Phase II Study of Coltuximab Ravtansine (SAR3419) Monotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
Conclusion Coltuximab ravtansine was well tolerated but was associated with a low clinical response rate in patients with relapsed or refractory ALL. Micro-Abstract Therapy options are limited for adult patients with relapsed or refractory acute lymphoblastic leukemia (ALL). In the present phase II study, 36 patients with relapsed or refractory ALL were treated with the anti-CD19 antibody-drug conjugate, coltuximab ravtansine. Coltuximab ravtansine was well tolerated, but the clinical response rate was low (4 of 17 patients). (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - January 14, 2016 Category: Cancer & Oncology Source Type: research

Comorbidities Drive Outcomes for Both Malignancy and Non-Malignancy Associated Hemophagocytic Syndrome
Conclusion Malignancy associated HPS, CI ≥ 2, age> 50, and Medicare patients were associated with a worse in-hospital mortality. In multivariate analysis, greater co-morbidity burden appeared to be the single most important predictor of mortality. This suggests that outcomes for adults with HPS are predicated by the extent of organ dysfunction at diagnosis. Teaser Secondary hemophagocytic syndrome (SHPS) is a rare syndrome that develops in the context of infection, autoimmune disease or an underlying malignancy resulting in unregulated activation of the immune system. Through a retrospective analysis of a large i...
Source: Clinical Lymphoma Myeloma and Leukemia - January 12, 2016 Category: Cancer & Oncology Source Type: research

Single-Agent Brentuximab as Bridging Therapy for Hodgkin Lymphoma Patients With Hepatic Impairment
Publication date: Available online 2 December 2015 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Arjun Gupta, Jan Petrasek, Shiraj Sen, Purva Gopal, Harris V. Naina (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - January 11, 2016 Category: Cancer & Oncology Source Type: research

Role of Surveillance Imaging in Patients With Peripheral T-Cell Lymphoma
Conclusion Most PTCL relapses were detected before planned SI, and most patients had symptoms with relapse. Only 3 patients (5.2%) were completely asymptomatic at relapse, suggesting a limited utility of routine imaging for detecting PTCL relapses. Micro-Abstract Data from aggressive lymphoma such as diffuse large B-cell lymphoma and Hodgkin lymphoma suggest a limited utility of surveillance imaging (SI) after achieving first complete remission. The present study of patients with peripheral T-cell lymphoma showed similar data, with most relapses detected apart from planned SI and associated with abnormal symptoms or signs...
Source: Clinical Lymphoma Myeloma and Leukemia - January 11, 2016 Category: Cancer & Oncology Source Type: research

Treatment of Osteonecrosis in Children and Adolescents with Acute Lymphoblastic Leukemia
Conclusions No standard of care exists for treatment of ALL-associated ON. While considerable practice variation exists, surgical intervention appears relatively safe. Teaser Osteonecrosis (ON) is a well-recognized complication of therapy for children with acute lymphoblastic leukemia (ALL). In this cohort of newly diagnosed ALL patients followed for up to five years, 2.33% incidence of ON was identified by ICD-9 code. Overall, 22.7% underwent some form of surgical management with considerable hospital variation in both the rate and type of surgical intervention. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - January 11, 2016 Category: Cancer & Oncology Source Type: research

CHOP chemotherapy followed by tositumomab and iodine-131 tositumomab for previously untreated diffuse large B-cell lymphoma
Publication date: Available online 4 January 2016 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): John P. Leonard, Stephanie A. Gregory, Hedy Smith, Thierry J. Horner, Vanessa C. Williams, Patricia Giampietro, Thomas S. Lin The efficacy and safety of tositumomab/iodine-131 tositumomab (TST/I-131 TST) were evaluated in diffuse large B-cell lymphoma patients who responded to first-line cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP). Fifteen patients (median age 52 years) received dosimetric and therapeutic doses of TST/I-131 TST. The most common Grade 3/4 hematologic adverse events were de...
Source: Clinical Lymphoma Myeloma and Leukemia - January 11, 2016 Category: Cancer & Oncology Source Type: research

Patient Characteristics and Outcomes in Adolescents and Young Adults (AYA) with Acute Myeloid Leukemia (AML)
Conclusion Outcome of AYA AML patients is overall better than for older adults with AML. Despite improvements in treatments and outcomes over time, there is still need for improvement in AYA with AML particularly for those with AML other than CBF and APL. Teaser Little is known about outcomes of AML in adolescents and young adults (AYA), a unique subgroup of AML patients. We retrospectively analyzed all AML patients (n=3,922) treated at our institution from 1965 to 2009 aged 16 to 29 years and found 432 (11%) AYA AML. Over time, outcomes for AYA AML patients have improved compared to older adults with AML. (Source: Clinica...
Source: Clinical Lymphoma Myeloma and Leukemia - January 11, 2016 Category: Cancer & Oncology Source Type: research

Clinical features and survival of follicular lymphoma patients in Korea
Conclusion We could not find definitive differences compared with western data, but we found some trends in baseline characteristics. Based on this, we hope to develop an understanding of FL and carry out more qualitative studies in the future. Teaser Retrospective analysis of 343 patients who diagnosed as follicular lymphoma in Korea showed some tendencies compare with western countries. The grade was high and the stage was low relatively. The Bcl-2 expression was low too. Except this, almost characteristics were similar. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - January 11, 2016 Category: Cancer & Oncology Source Type: research

A Single-Center Experience With Brentuximab Vedotin in Gamma Delta T-Cell Lymphoma
Publication date: Available online 1 December 2015 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Rakhshandra Talpur, Ramya Chockalingam, Casey Wang, Michael T. Tetzlaff, Madeleine Duvic (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - December 24, 2015 Category: Cancer & Oncology Source Type: research

Bing Neel Syndrome in a Previously Untreated Patient With Waldenström's Macroglobulinemia: Contribution of MYD88 L265P Mutation on Cerebrospinal Fluid
Publication date: Available online 2 December 2015 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Anna Maria Frustaci, Chiara Rusconi, Paola Picardi, Silvio Veronese, Marco Montillo, Roberto Cairoli, Alessandra Tedeschi (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - December 24, 2015 Category: Cancer & Oncology Source Type: research

Myxoma virus induces ligand independent extrinsic apoptosis in human myeloma cells
Conclusion Taken together, these results suggest that myxoma virus eliminates human multiple myeloma cells through a pathway unique to oncolytic poxviruses making it an excellent therapeutic option for the treatment of relapsed or refractory patients. Teaser We have previously shown that the myxoma virus kills human myeloma cells. Here we demonstrate that this killing occurs due to the ligand independent activation of caspase-8. We hypothesize that this activation is the result of viral host-protein shutoff depleting a variety of cellular inhibitors of apoptosis. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - December 24, 2015 Category: Cancer & Oncology Source Type: research

Prevalence and Prognostic Impact of Wilms' Tumor 1 (WT1) Gene, Including SNP rs16754 in Cytogenetically Normal Acute Myeloblastic Leukemia (CN-AML): An Iranian Experience
Conclusion WT1 gene mutations are a predictor indicator of a poor prognosis factor in CN-AML patients. It is recommended that WT1 gene mutations be included in the molecular testing panel in order to better diagnose and confirm their prognostic significance for better management and treatment strategy. Micro-Abstract To evaluate the effect of Wilms' tumor 1 (WT1) gene mutations in adult cytogenetically normal acute myeloblastic leukemia (AML) patients on survival and clinical outcome. Exons 7, 8, and 9 were evaluated in 88 adult patients with AML. Overall survival (OS) and disease-free survival (DFS) was significantly low...
Source: Clinical Lymphoma Myeloma and Leukemia - December 22, 2015 Category: Cancer & Oncology Source Type: research

Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (EPOCH) With or Without Rituximab as First-Line Therapy for Aggressive Non-Hodgkin Lymphoma
Conclusion Our data suggest that EPOCH with or without rituximab is active in both B- and T-cell aNHL. Toxicity did not significantly affect timing of treatment delivery or treatment outcomes. Dose adjustment by hematopoietic nadir similarly had no effect. The effect of smoking during chemotherapy should be evaluated further. Micro-Abstract The goal of the present study was to examine the risk factors and outcomes of 136 patients with aggressive non-Hodgkin lymphoma treated with dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin. Current smoking was a significant predictor of death, progre...
Source: Clinical Lymphoma Myeloma and Leukemia - December 22, 2015 Category: Cancer & Oncology Source Type: research

A Phase 2 Study of Coltuximab Ravtansine (SAR3419) Monotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)
Conclusions Coltuximab ravtansine is well tolerated but is associated with a low clinical response rate in patients with relapsed/refractory ALL. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - December 22, 2015 Category: Cancer & Oncology Source Type: research

Pharmacokinetics and Safety of Elotuzumab in Combination with Lenalidomide and Dexamethasone in Patients with Multiple Myeloma and Various Levels of Renal Impairment: Results of a Phase 1b Study
Conclusion This study supports the use of elotuzumab for the treatment of patients with MM and renal dysfunction without dose adjustment. Teaser Renal impairment is associated with poor prognosis in patients with multiple myeloma (MM) and more treatment options are needed. The pharmacokinetics of elotuzumab, a humanized IgG1 monoclonal antibody, in combination with lenalidomide and dexamethasone, is not significantly different between patients with MM with/without renal impairment, suggesting that elotuzumab may be administered without dose adjustment for renal function. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - December 22, 2015 Category: Cancer & Oncology Source Type: research

The role of surveillance imaging in patients with peripheral T-cell lymphoma
Conclusions The majority of PTCL relapses were detected prior to planned SI and most patients had symptoms on relapse. Only 3 patients (5.2%) were completely asymptomatic at relapse suggesting a limited utility of routine imaging in detecting PTCL relapses. Teaser Data from aggressive lymphoma such as diffuse large B-cell lymphoma and Hodgkin lymphoma suggest a limited utility of surveillance imaging (SI) after achieving first complete remission. This study in patients with peripheral T-cell lymphoma (PTCL) is similar in that it showed that most relapses are detected apart from planned SI and are associated with abnormal s...
Source: Clinical Lymphoma Myeloma and Leukemia - December 22, 2015 Category: Cancer & Oncology Source Type: research

Doxorubicin-based Chemotherapy and Radiation Therapy Produces Favorable Outcomes in Limited-Stage Plasmablastic Lymphoma: A Single-Institution Review
Conclusion PBL can be successfully treated with aggressive chemotherapy followed by RT. Treatment was well tolerated and can result in long-term survival for patients with limited-stage disease. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - December 22, 2015 Category: Cancer & Oncology Source Type: research

Imatinib increases serum creatinine by inhibiting its tubular secretion in a reversible fashion in chronic myeloid leukemia
Conclusion Imatinib completely blunts tubular secretion of creatinine, a previously unreported pharmacological property. This inhibition increases serum creatinine independently of any glomerular dysfunction and is fully reversible upon imatinib cessation. Teaser An increase in creatinine has been described in patients treated with imatinib for chronic myeloid leukemia but the underlying mechanism remains unknown. Thorough renal function exploration in 4 patients and populations of matched controls and prospective assessment of creatinine in patients who stopped imatinib or in whom therapy was changed to nilotinib led us t...
Source: Clinical Lymphoma Myeloma and Leukemia - December 20, 2015 Category: Cancer & Oncology Source Type: research